Abstract: Rational prescribing tools can be used by individual prescribers, organisations, and researchers to evaluate the quality of prescribing for research and quality improvement purposes. A literature search showed that there is only one tool for evaluating rational prescribing for paediatric patients in hospital and outpatient settings. The Pediatrics: Omission of Prescriptions and Inappropriate Prescriptions (POPI) tool was developed in France and comprises 105 criteria. The aim of this study was to modify this tool to facilitate its use in paediatric practice in the United Kingdom (UK). POPI criteria were compared to relevant UK clinical guidelines from the National Institute for Health and Care Excellence, the Scottish Intercollegiate Guideline Network and the British National Formulary for Children. Where guidelines differed, criteria were modified to reflect UK guidance. If there were no relevant guidelines or directly contradictory guidelines, criteria were removed. Overall, no change was made to 49 criteria. There were 29 modified to concord with UK guidelines. Four criteria were reduced to two criteria due to being linked in single guidelines. Twenty-three criteria were omitted, due to the absence of relevant UK guidance or directly conflicting UK practice, including one entire clinical category (mosquitos). One category title was amended to parallel UK terminology. The modified POPI (UK) tool comprises of eighty criteria and is the first rational prescribing tool for the evaluation of prescribing for children in hospital and outpatient settings in the UK.
Introduction
Rational prescribing describes practices aimed to optimise the use of medicines, encompassing safety, clinical effectiveness, access, and financial considerations. The WHO has defined rational prescribing as "when patients receive the appropriate medicines, in doses that meet their own individual requirements, for an adequate period of time, and at the lowest cost both to them and the community" [1] . Rational prescribing has been considered a problem mainly for low and lower middle-income countries, but it is increasingly being recognized as a problem in high-income countries [2, 3] .
Rational prescribing tools have been used, particularly in older adult medicine, as both research and quality improvement tools to investigate and improve rational prescribing [4] . These tools provide their users, whether individual prescribers, organizations, or research groups, with an objective measurement tool for the quality of prescribing according to rational prescribing principles. This facilitates research into factors involved in irrational prescribing, comparison across time or between
Materials and Methods
The 105 propositions of the POPI criteria were compared by one researcher (FC) to evidence-based UK clinical guidelines and clinical knowledge summaries from the National Institute of Health and Care Excellence (NICE) [7] , the Scottish Intercollegiate Guidelines Network (SIGN) [8] , the British National Formulary for Children (cBNF) [9] , and the European Medicines Agency (EMA) [10] . The national guidance from NICE, SIGN and the cBNF were preferred; EMA recommendations were referred to when no national guidelines were available. This process used the most recent guidelines available on 1st October 2015. Where amendments were made, the specific related guideline is cited.
Following the comparison with the guidelines, there were three possible outcomes:
• Guidelines concurred with the POPI propositions. No change was made.
•
There was partial discordance. POPI propositions were amended to match UK guidance.
There was no guidance available or the proposition was in complete discordance with guidance, the proposition was omitted.
The final wording of the modified POPI criteria was reached as consensus in consultation with two paediatric clinical pharmacology consultants.
Results
Overall, no change was made to 49 propositions. There were 29 amended to concord more closely with UK guidelines. Four were reduced into two propositions, as they were closely related and the relevant guidelines referred to them together, simplifying the tool. Twenty-three were omitted altogether, which included the omission of an entire category. One category title was amended, as the diagnosis of attention deficit disorder without hyperactivity is not in use in the UK.
The most substantial single change was the omission of the category of "mosquitos". There are currently no areas in the UK where insect-borne diseases are endemic. This was not considered applicable to UK practice and therefore the category comprising of seven propositions, was removed.
Some suggest that the viable habitat of mosquito vectors for vivax malaria may expand to the UK in the future, and if this were to occur, then this might be an appropriate area to target rational prescribing.
Twelve propositions were omitted due to a lack of relevant clinical guidelines (Table 1) . The majority of these related to inappropriate prescriptions for medicines that are either not used in the UK, e.g., Diosmectite, or not used by the rectal route, e.g., rectal paracetamol. Table 1 . Propositions omitted due to the absence of relevant UK clinical guidelines.
Symptom or Illness Category Omitted Paediatric Rational Prescribing Tool (POPI) Proposition
Pain and fever (inappropriate prescriptions). Rectal administration of paracetamol as a first-line treatment.
Pain and fever (omission). Failure to give sugar solution to newborn babies and infants under four months old two minutes prior to venipuncture.
Urinary infection (inappropriate prescription). Nitrofurantoin used as a prophylactic.
Diarrhoea (inappropriate prescription).
The use of Diosmectite (Smecta) in combination with another medication [medication not approved for use in the UK]. The use of Saccharomyces boulardii (Ultralevure) in powder form, or in a capsule that has to be opened prior to ingestion, to treat patients with a central venous catheter or an immunodeficiency.
Intestinal antiseptics.
Cough (inappropriate prescription).
Mucolytic drugs, mucokinetic drugs, or helicidine before two years of age. Alimemazine (Theralene), oxomemazine (Toplexil), promethazine (Phenergan, and other types).
Terpene-based suppositories.
Bronchiolitis (inappropriate prescription).
0.9% NaCl to relieve nasal congestion (not applicable if nasal congestion is already being treated with 3% NaCl delivered by a nebulizer).
ENT infections (inappropriate prescription). Ethanolamine tenoate (Rhinotrophyl) and other nasal antiseptics.
Acne vulgaris (inappropriate prescription).
Androgenic progestins (levonorgestrel, norgestrel, norethisterone, lynestrenol, dienogest, contraceptive implants or vaginal rings).
Four propositions were also omitted where UK clinical guidelines contradicted the proposition. These are listed in Table 2 with the relevant conflicting UK guideline. They included the use of nitrofurantoin for urinary tract infections in young children; fluoride supplements in infants under the age of six months: the use of setrons (5-HT3 antagonists) for nausea/vomiting in association with chemotherapy; and isotretinoin for adolescent acne.
Two propositions were combined with closely related propositions, where the recommendations were linked in a single UK guideline in order to make the modified tool as concise as possible. The original and combined propositions are shown below in Table 3 with the related UK guidance. These related to the use of medicines for infants with bronchiolitis and the use of antibiotics in children with otitis media/upper respiratory tract infections. There were 19 propositions that related to inappropriate prescriptions, and 10 propositions that related to inappropriate omissions that were amended to more closely concord with UK guidelines (Tables 4 and 5 ). In some instances, the age was changed, e.g., loperamide is considered inappropriate in the UK in children under the age of four years old, whereas in France it is under the age of three years old. Some medicines such as benzyl benzoate are not recommended at all in children in the UK. Some medicines such as sodium cromoglycate are not recommended at all in France, whereas in the UK it can be used for exercise-induced asthma. In addition, the category title of "Attention deficit disorder with or without hyperactivity" was amended to "Attention deficit hyperactivity disorder", as attention deficit disorder without hyperactivity is not recognised in UK clinical guidelines. Orally administered aciclovir to treat severe herpetic gingivostomatitis.
A strong dermocorticoid (clobetasol propionate 0.05% Dermoval, betamethasone dipropionate Diprosone) applied to the face, the armpits or groin, and the backside of babies or young children. (Atopic eczema) NICE guidance CG57: https://www.nice.org.uk/ guidance/CG57/chapter/1-Guidance (use mild potency for the face and neck, except for short-term (3-5 days) use of moderate potency for severe flares; use moderate or potent preparations for short periods only (7-14 days) for flares in vulnerable sites such as axillae and groin; do not use very potent preparations in children without specialist dermatological advice.) Children's BNF Dermoval not listed: http://www.evidence.nhs.uk/formulary/bnf/ current/13-skin/134-topical-corticosteroids/ topical-corticosteroid-preparation-potencies A potent topical corticosteroid applied to the face, or for >14 days applied to the axilla or groin. Antibiotic prophylaxis with phenoxymethylpenicillin (Oracilline) starting from two months of age and lasting until five years of age for children with sickle-cell anaemia: 100,000 IU/kg/day (in two doses) for children weighing 10kg or less and 50,000 IU/kg/day for children weighing over 10 kg (also in two doses). (Vitamin supplements and antibiotic prophylaxis) NICE Clinical Knowledge Summary: http: //cks.nice.org.uk/sickle-cell-disease#!scenario:3 (Explain that lifelong prophylaxis is recommended, but it is particularly important that there is full adherence up to five years of age. Prescribe phenoxymethylpenicillin (penicillin V) prophylaxis from the age of one month, at a dose of: 125 mg twice a day for infants and children up to five years of age. 250 mg twice a day for children from six to 12 years of age. 500 mg twice a day for adults and children older than 12 years of age. Erythromycin is recommended for people who are allergic to penicillin, at a dose of: 125 mg twice a day for infants and children up to two years of age. 250 mg twice a day for adults and children older than two years of age.) Antibiotic prophylaxis with phenoxyethylpenicillin (penicillin V) from age one month until five years old for children with sickle-cell anaemia at a dose of: 125 mg twice a day for infants and children up to five years of age. 250 mg twice a day for children from six to 12 years of age. 500 mg twice a day for adults and children older than 12 years of age. Or Erythromycin for children who are allergic to penicillin, at a dose of: 125 mg twice a day for infants and children up to two years of age. 250 mg twice a day for children older than two years of age. 
Modified POPI Proposition-Inappropriate Omission
Failure to propose a whooping cough booster vaccine for adults who are likely to become parents in the coming months or years (only applicable if the previous vaccination was more than 10 years ago). This booster vaccination should also be proposed to the family and entourage of expectant parents (parents, grandparents, nannies/child minders). (Cough).
NICE CKS Antenatal care of uncomplicated pregnancy: http://cks.nice.org.uk/antenatal-careuncomplicated-pregnancy#!scenario (28 weeks gestation: Offer vaccination against pertussis.) Amend: Failure to propose a whooping cough vaccine for pregnant women.
Palivizumab in the following cases: (1) babies born both at less than 35 weeks of gestation and less than six months prior to the onset of a seasonal RSV epidemic; (2) children less than two years old who have received treatment for bronchopulmonary dysplasia in the past six months; (3) children less than two years old suffering from congenital heart disease with hemodynamic abnormalities. (Bronchiolitis in infants).
SIGN guidance 91 (Bronchiolitis in children): http:// www.sign.ac.uk/guidelines/fulltext/91/index.html ( . . . recommends use of palivizumab in high risk groups, as defined by the committee (children under two years of age with chronic lung disease, on home oxygen or who have had prolonged use of oxygen; infants less than six months of age who have left to right shunt haemodynamically significant congenital heart disease and/or pulmonary hypertension; children under two years of age with severe congenital immuno-deficiency).)
Amend: Palivizumab in high-risk cases, defined as: children <2 years with chronic lung disease on home oxygen or who have prolonged use of oxygen; infants <6 months with left-to-right shunt haemodynamically significant congenital heart disease and/or pulmonary hypertension; children <2 years with severe congenital immunodeficiency.)
Asthma inhaler appropriate for the child's age. (Asthma) NICE guidance TA10: https://www.nice.org.uk/guidance/ta10 (NICE has recommended that for children under the age of five years who have chronic stable asthma: both corticosteroids and bronchodilator therapy should routinely be delivered by Pressurised Metered Dose Inhaler (pMDI) and spacer system, with a facemask where necessary. Where this combination is not clinically effective for the child, and depending on the child's condition, nebulised therapy may be considered and in the case of children aged 3-5 years, a dry powder inhaler (DPI) may also be considered. The choice of which pMDI device and spacer to use should be determined by the specific needs of the child and how well it works for them. Once these factors have been taken into account the choice should be made on the basis of reducing costs.) Others involved minor changes in relation to dosing and age for penicillin prophylaxis for children with sickle cell disease; patient groups for palivizumab: or vitamin use in infants.
The resulting modified POPI criteria therefore comprise 80 propositions assessing rational prescribing for children in accordance with up-to-date UK guidelines (see Table 6 ). Table 6 . The modified POPI (UK) tool.
DIVERSE ILLNESSES

PAIN AND FEVER
Inappropriate prescriptions. Prescription of two alternating antipyretics as a first-line treatment. Prescription of a medication other than paracetamol or ibuprofen as a first-line treatment for pain (except in the case of a migraine). The combined use of two NSAIDs. Doses of ibuprofen administered in more than three doses per day or exceeding maximum dose of 30 mg/kg daily in three doses per day. Opiates to treat migraine attacks. Omissions. Failure to give an osmotic laxative to patients being treated with morphine for a period of more than 48 h.
URINARY INFECTIONS
Inappropriate prescriptions. Antibiotic prophylaxis following an initial infection without complications (except in the case of uropathy). Antibiotic prophylaxis in the case of asymptomatic bacterial infection (except in the case of uropathy).
VITAMIN SUPPLEMENTS AND ANTIBIOTIC PROPHYLAXIS
Omissions. Healthy Start vitamins for infants and children 0.5-5 years or having less than 500 mL infant formula per day. Antibiotic prophylaxis with phenoxyethylpenicillin (penicillin V) from age one month until five years for children with sickle-cell anaemia at a dose of:
• 125 mg twice a day for infants and children up to five years of age.
• 250 mg twice a day for children from six to 12 years of age.
• 500 mg twice a day for adults and children older than 12 years of age.
Or Erythromycin for children who are allergic to penicillin, at a dose of:
• 125 mg twice a day for infants and children up to two years of age.
• 250 mg twice a day for children older than two years of age.
DIGESTIVE PROBLEMS
NAUSEA, VOMITING, OR GASTROESOPHAGEAL REFLUX Inappropriate prescriptions. Metoclopramide. Domperidone. Oral administration of an intravenous proton pump inhibitor (notably by nasogastric tube). Acid-suppressing drugs to treat overt regurgitation in the absence of feeding difficulties, distress, or faltering growth. The combined use of proton pump inhibitors and NSAIDs, for a short period of time, in patients without risk factors. The use of H2 receptor antagonists for more than four weeks. Erythromycin. Omissions. Oral rehydration solution (ORS) for dehydrated children unless IV fluid therapy is indicated (shock, red flag symptoms despite ORS, persist vomiting of ORS).
DIARRHOEA
Inappropriate prescriptions. Loperamide before four years of age. Loperamide in the case of invasive diarrhoea. Omissions. Oral rehydration solution (ORS) for dehydrated children unless IV fluid therapy is indicated (shock, red flag symptoms despite ORS, persist vomiting of ORS). Table 6 . Cont.
ENT-PULMONARY PROBLEMS
COUGH
Inappropriate prescriptions. Pholcodine.
Omissions. Failure to propose a whooping cough vaccine for pregnant women.
BRONCHIOLITIS IN INFANTS
Inappropriate prescriptions. Antibiotics, Beta2 agonists or corticosteroids to treat bronchiolitis. H1-antagonists, cough suppressants, mucolytic drugs, or ribavirin to treat bronchiolitis. Omissions. Palivizumab in high-risk cases, defined as:
• Children <2 years with chronic lung disease on home oxygen or who have prolonged use of oxygen; • Infants <6 months with left-to-right shunt haemodynamically significant congenital heart disease and/or pulmonary hypertension; • Children <2 years with severe congenital immunodeficiency.
ENT INFECTIONS
Inappropriate prescriptions. An antibiotic for <4 days symptoms of acute upper respiratory tract infection (except:
• Bilateral acute otitis media in children younger than two years; • Acute otitis media in children with otorrhoea; • Acute sore throat/acute pharyngitis/acute tonsillitis when three or more Centor criteria are present.) Antibiotic treatment for a sore throat except in severe cases (anticipated to be no more than 20% of cases). Antibiotics to treat otitis media with effusion in the first 6-12 weeks. Corticosteroids to treat acute suppurative otitis media, nasopharyngitis, or strep throat. Nasal or oral decongestant (oxymetazoline (Aturgyl), pseudoephedrine (Sudafed), naphazoline (Derinox), ephedrine (Rhinamide), tuaminoheptane (Rhinofluimicil), phenylephrine (Humoxal)). Sedating antihistamines (pheniramine, chlorpheniramine) before two years (except for anaphylaxis). Eardrops in the case of acute otitis media. A potent topical corticosteroid applied to the face, or for >14 days applied to the axilla or groin. More than one application per day of a dermocorticoid, except in cases of severe lichenification. Prescription of antihistamines except as a trial for severe itching or where sleep disturbance has a significant impact on the child or carers. Topically applied 0.03% tacrolimus before two years of age. Topically applied 0.1% tacrolimus before 16 years of age. Oral corticosteroids to treat outbreaks.
NEUROPSYCHIATRIC DISORDERS
EPILEPSY
Inappropriate prescriptions. Carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine, or vigabatrin in the case of myoclonic epilepsy. Carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine, or vigabatrin in the case of epilepsy with absence seizures (especially for childhood absence epilepsy or juvenile absence epilepsy). Levetiracetam, oxcarbamazepine in mL or in mg without systematically writing XX mg per Y mL.
DEPRESSION
Inappropriate prescriptions. An SSRI antidepressant other than fluoxetine as a first-line treatment (in the case of pharmacotherapy). Tricyclic antidepressants to treat depression. 
Discussion
The POPI criteria were modified to develop a list of potentially inappropriate prescriptions and omissions for children in the UK.
Over half of the propositions of the POPI criteria were altered. The majority of those changes were subtle modifications to bring the wording of propositions more closely in line with the specific wording of UK clinical guidelines. In other cases, the propositions were directly in contradiction of relevant guidelines and were amended accordingly. In order for this tool to be useful in appraising rational prescribing in the UK, it is important that prescribers are being measured against the specific standards they are striving for, and this would also facilitate straightforward interventions using UK guidelines for education and service improvement.
For 22 propositions, there were no relevant UK clinical guidelines. Absence from guidelines does not necessarily invalidate the recommendations of those propositions but the propositions were omitted, as they appeared to relate to the irrational use of medicines that do not appear to be prevalent in the UK. In some cases, the propositions related to medications not available in the UK. For instance, in the case of diosmectite for diarrhoea, there is some emerging evidence supporting its use [11] but this is not reflected in the availability of the product in the UK.
In other cases, differing national practices may explain the absence if the type of irrational prescribing described is already rare in UK practise. This explanation likely underlies guidance about rectally administered drugs including paracetamol per rectum for pain and suppositories for cough. The cultural difference that may give rise to this variance in clinical practice was recognised in the European Medicines Agency Guideline on pharmaceutical development of medicines for paediatric use [12] when discussing medication acceptability in different countries, giving the example that "the rectal route of administration is not generally favoured in the UK".
Two of the omitted propositions, in relation to sucrose for painful procedures in infants and nitrofurantoin as prophylaxis for urinary infection, may be absent from national UK guidelines because these are areas where there is not a national consensus of best practice. In reviewing these topics, local guidelines were found to differ, including some recommending nitrofurantoin for that purpose [13, 14] and some preferring breast or bottle-feeding over sucrose, recommending contraindications and qualifying the guideline according to gestation and the age of the infant [15, 16] . In the absence of a unifying national guideline on these topics, they were therefore not considered to be good candidates for screening prescribing practice nationally.
Four propositions were omitted due to the existence of UK clinical guidelines that were in direct conflict with the original proposition (see Table 2 ).
Three of these appear to have been included as potentially inappropriate prescriptions in the original French tool due to the risk of interactions or side effects. One related to nitrofurantoin for the treatment of urinary infections. According to the report describing the development of the original POPI tool, this proposition was derived from a statement issued by AFSSAPS (the French Agency for the Safety of Health Products, Agence Française de Sécurité Sanitaire des Produits de Santé) in 2011, warning of cases of severe hepatic and pulmonary complications following long-term treatment with nitrofurantoin [17] .
The cBNF does recommend monitoring liver function and for pulmonary symptoms if prescribing nitrofurantoin long-term, but it is licensed and indicated in acute uncomplicated urinary tract infections for children aged three months and older [9] and is second-line for children aged three months and older in the most recent NICE guideline NG109 [7] .
The second related to isotretinoin and tetracycline antibiotics. This appears to be derived from a Good Practice Recommendation from AFSSAP describing isotretinoin as contraindicated with tetracyclines due to the reported occurrence of benign intracranial hyptertension with this combination [18] . This risk is recorded in the cBNF as a possible interaction, rated as "serious" with an anecdotal evidence base [9] . The combination is not recorded as a contraindication and combined topical retinoids and oral tetracyclines and recommended in the NICE Clinical Knowledge Summary.
The third related to fluoride supplements before age six months. The related French guideline, an AFSAPPS statement in 2008, recommended that fluoride containing supplements such as toothpaste, commence when teeth erupt, on average at age six months [19] . This statement, like the relevant UK guidelines, discusses the risk of dental fluorosis with excess fluoride consumption during tooth development and recommends lower dose fluoride in toothpaste for young children. Both the NICE and SIGN guidelines quoted in Table 2 acknowledge the risk of dental fluorosis and state that the benefit of reduced caries favours starting fluoride supplementation as soon as teeth erupt with no definitive lower age limit of benefit to the child.
These all appear to reflect differing risk tolerance between the French and UK guidelines. In order that the modified tool reflects what is considered nationally to be good practice, the propositions were therefore omitted from the modified tool.
The fourth omitted proposition listed, "The use of setrons (5-HT3 antagonists) for chemotherapyassociated nausea and vomiting", as a potentially inappropriate prescription. It was not clear what evidence was used to develop this proposition as none of the references in the report describing the development of the original tool related to chemotherapy-associated nausea and vomiting. One reference from the American Centers for Disease Control and Prevention recommended ondansetron as an anti-emetic for children [20] . It is possible that the inclusion of this criterion in the original tool constitutes a typographical error, and that it was intended to read as an inappropriate omission, given the importance of treating chemotherapy-associated nausea. It was therefore felt not to accurately reflect rational prescribing and was omitted from the modified tool.
Following the described amendments, the modified POPI(UK) tool comprises eighty criteria describing potentially inappropriate prescriptions or omissions. This tool is intended to evaluate the quality of prescribing for children in both hospital and outpatient settings, and is not limited to a specific group of prescribers. Similar tools for evaluating rational prescribing for older adults have facilitated a broad range of research, including research into quality of prescribing across different settings [21] , studies into healthcare outcomes associated with irrational prescribing [22] , and to predict adverse health outcomes in patient groups [23] . The tool is not intended for routine use by individual prescribers, as it requires experience to use.
Conclusions
The modified POPI (UK) criteria comprise the first screening tool available to assess rational prescribing for children in UK hospitals and outpatient settings. Clinical validation and reliability studies are needed and planned by the authors in order to evaluate the usability and reliability of this tool, which it is hoped will be used to study the rational use of medicines in children in the UK. 
